Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery

Catheterization and Cardiovascular Interventions

Volumn 53, Issue 4, 2001, Pages 562-568

  Oberhoff, Martin ^a   Herdeg, Christian ^b   Ghobainy, Rasool Al ^a   Cetin, Sha ^a   Kttner, Axel ^a   Horch, Barbara ^b   Baumbach, Andreas ^a   Karsch, Karl R ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Angioplasty; Local drug delivery; Paclitaxel; Pig; Restenosis

Indexed keywords

PACLITAXEL;

ANIMAL EXPERIMENT; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; NONHUMAN; RESTENOSIS; SWINE;

ANGIOPLASTY, BALLOON; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATHETERIZATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ELECTROCARDIOGRAPHY; INFUSION PUMPS; PACLITAXEL; STENTS; SWINE;

EID: 0034908836     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1223     Document Type: Article

References (30)

1. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group
2. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators
3. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study
4. Dealing with in-stent restenosis
5. Balloon angioplasty for treatment of in-stent restenosis: Feasibility, safety, and efficacy
6. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia
7. Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries
8. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model
9. Prolonged proliferative response of smooth muscle cells after experimental intravascular stenting
10. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue
11. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
12. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue
13. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo
14. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat
15. Taxol: A novel investigational antimicrotubule agent
16. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery
17. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo
18. Differential neointimal response to coronary artery injury in pigs and dogs: Implications for restenosis models
19. Neointimal thickening after severe coronary artery injury is limited by a short-term administration of a factor Xa inhibitor: Results in a porcine model
20. Promotion of microtubule assembly in vitro by taxol
21. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins
22. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel
23. Distribution of microtubule organizing centers in migrating sheets of endothelial cells
24. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat
25. Local drug delivery: Impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall
26. Sustained stentbased delivery of paclitaxel arrests neointimal thickening and cell proliferation
27. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres
28. Cardiac disturbances during the administration of taxol